Published in

American Academy of Neurology (AAN), Neurology: Clinical Practice, p. 10.1212/CPJ.0000000000001116, 2021

DOI: 10.1212/cpj.0000000000001116

Links

Tools

Export citation

Search in Google Scholar

CSF and Circulating NfL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes

Journal article published in 2021 by Efthalia Angelopoulou, Anastasia Bougea ORCID, Andreas Papadopoulos ORCID, Nikolaos Papagiannakis ORCID, Athina-Maria Simitsi ORCID, Christos Koros ORCID, Marios K. Georgakis ORCID, Leonidas Stefanis ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract:Purposeof review: To evaluate whether CSF and circulating neurofilament light chain (NFL), a marker of axonal damage, could discriminate Parkinson’s disease (PD) from atypical parkinsonian syndromes (APS).Recent findings:MEDLINE and SCOPUS were systematically searched, and fifteen studies were included (1035 PD patients,930 APS patients). CSF and circulating NFL levels were 1.26 and 1.53 standard deviations higher in APS compared to PD patients respectively [g=1.26 (95% CI 0.99-1.53);12 studies, 880 PD patients, 847 APS patients, g=1.53 (1.15-1.91);4 studies, 307 PD patients, 197 APS patients. Pooled areas under the curve were 0.941 (0.916-0.965) and 0.874 (0.802-0.946) for CSF and circulating NFL, corresponding to average sensitivities of 86% (79-90%) and 91% (86-95%), and specificity of 88% (82-92%) and 76% (62-85%), respectively.Summary:These results strongly support the high diagnostic accuracy of both CSF and circulating NFL in differentiating PD from APS, highlighting their usefulness as promising biomarkers.